BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2801676)

  • 1. Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus.
    Fiorucci S; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1989 Oct; 84(10):1263-7. PubMed ID: 2801676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present.
    Singh P; Taylor RH; Colin-Jones DG
    Am J Gastroenterol; 1994 Mar; 89(3):349-56. PubMed ID: 8122643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
    Fiorucci S; Santucci L; Morelli A
    Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?
    Coenraad M; Masclee AA; Straathof JW; Ganesh S; Griffioen G; Lamers CB
    Am J Gastroenterol; 1998 Jul; 93(7):1068-72. PubMed ID: 9672332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M; Müller M; Zeitz M
    Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional foregut abnormalities in Barrett's esophagus.
    Stein HJ; Hoeft S; DeMeester TR
    J Thorac Cardiovasc Surg; 1993 Jan; 105(1):107-11. PubMed ID: 8419690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan.
    Abe Y; Ohara S; Koike T; Sekine H; Iijima K; Kawamura M; Imatani A; Kato K; Shimosegawa T
    Am J Gastroenterol; 2004 Jul; 99(7):1213-21. PubMed ID: 15233656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus.
    Loughney T; Maydonovitch CL; Wong RK
    Am J Gastroenterol; 1998 Jun; 93(6):916-9. PubMed ID: 9647018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
    Ouatu-Lascar R; Triadafilopoulos G
    Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
    Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
    Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.
    Katzka DA; Castell DO
    Am J Gastroenterol; 1994 Jul; 89(7):989-91. PubMed ID: 8017396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barrett's esophagus in patients with symptomatic reflux esophagitis.
    Mann NS; Tsai MF; Nair PK
    Am J Gastroenterol; 1989 Dec; 84(12):1494-6. PubMed ID: 2596449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
    Triadafilopoulos G; Kaczynska M; Iwane M
    Am J Gastroenterol; 1996 Jan; 91(1):65-74. PubMed ID: 8561146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
    Sharma P; Sampliner RE; Camargo E
    Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of acid and alkaline reflux in patients with Barrett's esophagus. G.O.S.P.E. Operative Group for the study of Esophageal Precancer.
    D'Onofrio V; Bovero E; Iaquinto G
    Dis Esophagus; 1997 Jan; 10(1):16-22; discussion 22-3. PubMed ID: 9079268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
    Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of intestinal metaplasia in the gastric cardia.
    El-Serag HB; Sonnenberg A; Jamal MM; Kunkel D; Crooks L; Feddersen RM
    Am J Gastroenterol; 1999 Mar; 94(3):622-7. PubMed ID: 10086641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.